Highlights:
- Finerenone reduces the risk of cardiovascular-related mortality and
hospitalization, as well as nonfatal MI.
- Finerenone reduces the risk of renal failure, end-stage renal disease,
decline in eGFR, and death from renal causes.
- In addition, finerenone decreases the risk of death and
hospitalization from any cause.
- Finerenone posed a comparable risk of adverse events compared to
placebo, but the risk of serious adverse events was lower.